维里迪安治疗 VRDN

Mr. Mahoney has served as our President and Chief Executive Officer and a member of our Board since October 2023. Mr. Mahoney has more than two decades of experience in a variety of operational, financial, commercial, legal and transactional roles in companies of different sizes and stages. He has been successful scaling organizations from founding team through commercial stage. Prior to joining Viridian, Mr. Mahoney was the Chief Financial and Operating Officer of Magenta Therapeutics, Inc., where he drove operational excellence and disciplined capital allocation to high priority programs. Previously, Mr. Mahoney was part of the founding team of Kiniksa Pharmaceuticals, where he served as President and Chief Operating Officer. Prior to Kiniksa, he was Chief Commercial Officer of Synageva Biopharma, a company focused on ultrarare diseases, where he held roles of increasing responsibility in operations, commercial launch preparation, legal and corporate development. Mr. Mahoney was also a commercial attorney with Genzyme Corporation for approximately ten years. Prior to Genzyme, Mr. Mahoney was a corporate attorney with the law firm Mintz Levin. Mr. Mahoney received his M.B.A. from Boston College's Carroll School of Management, a J.D. from Boston College Law School, and a B.A. from Colorado College. He serves on the board of directors of Vesselon, Inc., a private company.

Dr. Radhika Tripuraneni joined Viridian in 2024 as a consultant and was appointed Chief Medical Officer in March 2025. Dr. Tripuraneni has over 25 years of experience in drug development across various functions of clinical science, medical affairs and business development. From September 2022 to March 2025, Dr. Tripuraneni worked as independent consultant with various venture capital firms, investment funds and biotech companies to develop strategic clinical development plans and support investment diligence. Dr. Tripuraneni previously served as Prothena's Chief Development Officer from April 2018 to September 2022 supporting the development of assets from pre-IND to Phase 3 and oversaw clinical development, biometrics, clinical operations and medical affairs. Prior to joining Prothena, Dr. Tripuraneni was Vice President, Medical Affairs and Chief of Staff to the Chief Medical Officer of MyoKardia Inc. Earlier in her career, Dr. Tripuraneni held various medical and business development positions of increasing responsibility at Alexion Pharmaceuticals, Synageva BioPharma, Gilead Sciences, Inc, and Genzyme Corp. Additionally, Dr. Tripuraneni was Chief Medical Officer at Summer Street Research Partners, a healthcare equity research firm. She is also on the board of Terns Pharmaceuticals as an independent director. Dr. Tripuraneni earned her bachelor's degrees in business administration and liberal arts as well as her M.D. from the University of Missouri, and her Master's in Public Health from Harvard University. She did her clinical training in general surgery at Harvard - Beth Israel Deaconess Medical Center.

Mr. Beetham has served as our Chief Operating Officer since October 2023. Mr. Beetham has more than 25 years of experience in operations, business development, strategy and legal in the biopharmaceutical industry. Mr. Beetham joined Viridian after serving as Chief Legal Officer of Magenta Therapeutics, Inc. from June 2021 to September 2023. Prior to Magenta, Mr. Beetham was part of the founding team of Kiniksa Pharmaceuticals where he served as Executive Vice President, Corporate Development and Operations, and Chief Legal Officer from July 2015 to June 2021, and had reporting responsibility for multiple functions, including strategy, business development, technical operations, medical affairs, value and access, legal, compliance, quality and human resources. Prior to Kiniksa, Mr. Beetham served as Senior Vice President, Chief Legal Officer and Corporate Development of Synageva BioPharma Corp. Prior to Synageva, Mr. Beetham was General Legal Counsel for New England Biolabs, Inc., and earlier, was the lead corporate attorney for Genzyme Corporation's Oncology and Multiple Sclerosis business units. Mr. Beetham received his M.B.A. from Boston College's Carroll School of Management, a J.D. from Boston College Law School, and a B.A. from the University of Rochester.

Mr. Harmon has served as our Chief Financial Officer since January 2025. Mr. Harmon previously served as our Senior Vice President of Finance and Accounting from May 2023 to January 2025. Mr. Harmon has served as our principal financial and accounting officer since September 2023. Mr. Harmon brings 20 years of strategic finance, accounting, and operations experience to his position. Prior to joining Viridian, Mr. Harmon served as the Chief Financial Officer of BioNTech US from May 2020 to May 2023, where he oversaw the general and administrative functions for BioNTech SE's U.S. subsidiary and served as a member of the BioNTech U.S. management team supporting the growth of the organization from 56 to over 500 employees. Earlier in his career he served as Vice President of Finance at Neon Therapeutics where he contributed to the company's successful $100 million initial public offering and subsequently oversaw the financial aspects of the company's restructure and strategic sale to BioNTech SE. Prior to Neon Therapeutics, Mr. Harmon held several positions with increasing levels of responsibility at Merrimack Pharmaceuticals, Inc., where he participated in the successful launch of the company's first commercial product and the subsequent sale of this asset to Ipsen. Mr. Harmon holds an M.S. in Accounting and M.B.A. from Northeastern University and obtained his certified public accountant license while working at Ernst and Young, LLP. Mr. Harmon received his B.A. in Economics and Mathematics from Bowdoin College.

Ms. Tousignant joined Viridian as Chief Legal Officer in February 2024. Ms. Tousignant has broad legal experience and leadership in the biotechnology industry working across a breadth of technologies such as small molecules, biologics, cell and gene therapies, and in the therapeutic categories of rare disease, immune-mediated disease, neurodegenerative disease, and oncology. Prior to Viridian, Ms. Tousignant served as Senior Vice President of Legal for Sana Biotechnology, Inc. from October 2020 to February 2024, where she was leading a team responsible for legal support for strategic transactions, business development, intellectual property, litigation, quality, regulatory, research and development, investor relations, and general contracting as well as being involved in corporate governance and financings. She joined Sana from Xilio Therapeutics, Inc., where she was the Head of Legal and responsible for all legal and compliance matters. Prior to Xilio, Ms. Tousignant was Chief IP Counsel at TESARO, where she built and led the intellectual property function, and was a key member of the global launch teams for several products. Before TESARO, she worked at Genzyme Corporation in roles of increasing responsibility, first in research and then in legal, and ultimately leading a legal team with worldwide intellectual property responsibility for products from early research to commercial. She is also a cofounder and serves as a director of a private biotechnology company. Ms. Tousignant received her J.D. from Suffolk University School of Law, and her B.A. in Chemistry from the University of Virginia.

Dr. Cain has served as a member of our Board since March 2025. Dr. Cain is the Director of Research at Fairmount Funds Management LLC, a healthcare investment firm. Prior to joining Fairmount, Dr. Cain served in various positions at the healthcare funds Samsara BioCapital, Apple Tree Partners, and RA Capital Management, where he invested in both public and emerging private biotechnology companies. Previously, Dr. Cain was a writer and editor at BioCentury Publications. He also serves as a director of Cogent Biosciences, Inc., Jade Biosciences, Inc., and Damora Therapeutics, Inc. He received a B.A. from the University of California, Santa Barbara and a Ph.D. in Biochemistry and Molecular Biology from the University of California, San Francisco.

Mr. Ajer has served as a member of our Board since April 2025. Mr. Ajer has more than 25 years of experience driving commercialization for rare diseases and specialty medicines, including leading commercial planning for late-stage pipeline programs, product marketing, reimbursement, and sales operations. He currently serves as the Chief Commercial Officer of Mendra, a venture-backed company focused on rare diseases. He previously served as the Executive Vice President and Chief Commercial Officer at BioMarin Pharmaceutical, Inc., where he joined in 2005 as one of the first sales and marketing employees and subsequently held roles of increasing responsibility that helped to establish BioMarin's commercial infrastructure and global footprint. Mr. Ajer had direct responsibility for the launch of 5 brands during his time as Chief Commercial Officer of BioMarin. Prior to BioMarin, Mr. Ajer served as Vice President, Global Transplant Operations at Genzyme Corporation and held positions in sales, marketing, and operations at SangStat Medical Corporation and ICN Pharmaceuticals. He also serves on the board of Nektar Therapeutics, a public biotech company. He received his B.S. degree in Chemistry and M.B.A. from the University of California, Irvine.

Mr. Kiselak has served as Chairman since June 2021 and a member of our Board since October 2020. Mr. Kiselak is a Founding Partner at Fairmount Funds Management LLC, a healthcare investment firm he co-founded in April 2016. Prior to Fairmount, Mr. Kiselak was a managing director at RA Capital Management, LLC. He also serves as a director of Apogee Therapeutics, Inc., Jade Biosciences, Inc., Spyre Therapeutics, Inc., and Zenas BioPharma, Inc., as well as several private companies. Until March 2025, Mr. Kiselak served as a director of Dianthus Therapeutics, Inc. He received a bachelor's degree in Neuroscience and Economics from Amherst College.

Ms. Morris has served as a member of our Board since January 2018. Ms. Morris currently serves as Chief Executive Officer at Willow Advisors, LLC, a consultancy advising biotech companies on financing, strategy and business development. Previously, she served as the President, Chief Executive Officer and a member of the board of directors of Syndax Pharmaceuticals, Inc, a privately held biotechnology company, and Affymax, Inc., a publicly traded biotechnology company. Ms. Morris has also held executive positions at Clearview Projects, Inc., Coulter Pharmaceutical, Inc., Scios Inc., Johnson & Johnson and board of director roles at Biodel Inc., Dimension Therapeutics, Inc. and Viveve, Inc. Ms. Morris also serves as a director of Palatin Technologies, Inc., Edgewise Therapeutics, Inc., and Cogent Biosciences, Inc., as well as the Charleston Animal Society. Ms Morris received a B.A. in Biology and Chemistry from Carlow University.

Ms. Moses has served as a member of our Board since July 2021. Ms. Moses is currently the Chief Financial Officer of Investors Management Corporation (IMC). Prior to joining IMC, Ms. Moses served as Chief Financial Officer of G1 Therapeutics, Inc., a commercial-stage oncology company. Previously, Ms. Moses was a partner at Rankin McKenzie, LLC, where she served as acting chief financial officer and controller for venture-backed companies. Before joining Rankin McKenzie, Ms. Moses held roles of increasing responsibility at Deloitte, including providing tax services to clients and later focusing on strategic planning and internal communications in the Office of the CEO of Deloitte Tax. Ms. Moses also serves as a director on the boards of various private companies. Ms. Moses received her B.S. in Accounting from The Pennsylvania State University and is a certified public accountant in the State of North Carolina.

Dr. Gheuens has served as a member of our Board since September 2023. Dr. Gheuens has served as Chief Medical Officer of Agios Pharmaceuticals, Inc., a pharmaceutical company since 2021 and as Agios's Head of Research and Development since 2022. Prior to joining Agios, Dr. Gheuens worked at Biogen, where she held roles of increasing responsibility in safety, medical affairs and clinical development. Her work was critical for the approval of SPINRAZA. Before joining Biogen, Dr. Gheuens worked at Beth Israel Deaconess Medical Center (BIDMC), taking care of patients with HIV and neurological complications and doing research on progressive multifocal leukoencephalopathy. Dr. Gheuens received her medical degree from the Free University of Brussels, Belgium, and completed her neurology residency at the University Hospital of the Free University of Brussels, Belgium, followed by an HIV/neurology fellowship at BIDMC. She also holds a Ph.D. in Medical Sciences from the University of Antwerp, Belgium, and a Master's in Medical Sciences from Harvard Medical School.